New drug trial aims to tame esophageal inflammation
NCT ID NCT05485155
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called Zemaira in 15 adults with eosinophilic esophagitis, a condition where white blood cells build up in the esophagus, causing pain and trouble swallowing. Participants receive Zemaira infusions for 4 weeks to see if it reduces inflammation and improves symptoms. The goal is to control the disease, not cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC ESOPHAGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
-
The National Institutes of Health
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Swallowable sponge could replace endoscopy for esophagitis monitoring
- Blood tests may replace scopes for EoE diagnosis
- Massive new registry aims to crack the code on mysterious gut disorders
- 300 kids with EoE enrolled in landmark database study
- Could ditching milk soothe a painful esophagus? new trial tests Diet-Only approach
- Can cutting four foods ease Kids' esophagus inflammation?